Los puntos clave no están disponibles para este artículo en este momento.
Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.
Lesokhin et al. (Mon,) studied this question.